Herantis Marks A Successful 2021; An Ambitious and Promising 2022 Ahead to Advance Robust CNS Pipeline
Herantis Pharma Plc, Press Release, 13 January 2022 at 09:00 EET Dr Craig Cook, CEO, commented ”2021 was indeed a defining year for Herantis as we move into the next chapter for the company and our programs. The year saw us focus all our research and resources on the key value drivers of the company – our CNS assets - allowing the true fundamentals of the company to take center stage. The cutting-edge science and the multimodal mechanism-of-action gives our assets the opportunity to be truly disease modifying therapies - in other words, they have the ability to slow, stop or even